AC IMMUNE SA SF-02 Total Assets
AC IMMUNE SA SF-02 total assets. Based on the latest financial reports, AC IMMUNE SA SF-02 (IMR) holds total assets worth €150.40 Million EUR (≈ $175.83 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see IMR stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of AC IMMUNE SA SF-02 (2021–2025)
Total assets of AC IMMUNE SA SF-02 from 2021 to 2025. This chart illustrates how AC IMMUNE SA SF-02's total assets have evolved over time, based on quarterly financial data. See AC IMMUNE SA SF-02 stock quote for real-time trading data and today's change.
AC IMMUNE SA SF-02 - Asset Composition Analysis
AC IMMUNE SA SF-02 Total Assets Breakdown (December 2025)
AC IMMUNE SA SF-02 total assets breakdown as of December 2025. AC IMMUNE SA SF-02's total assets of €150.40 Million consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €50.42 Million | 32.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how AC IMMUNE SA SF-02's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IMR net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AC IMMUNE SA SF-02's current assets represent 62.7% of total assets in 2025, a decrease from 77.5% in 2021.
- Cash Position: Cash and equivalents constituted 17.4% of total assets in 2025, down from 31.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 19.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 32.7% of total assets.
AC IMMUNE SA SF-02 Competitors by Total Assets
Key competitors of AC IMMUNE SA SF-02 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
AC IMMUNE SA SF-02 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 1.33 | 1.86 |
| Quick Ratio | 0.93 | 1.33 | 1.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-6.84 Million | €32.84 Million | €86.60 Million |
AC IMMUNE SA SF-02 - Advanced Valuation Insights
This section examines the relationship between AC IMMUNE SA SF-02's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.30 |
| Latest Market Cap to Assets Ratio | 1.40 |
| Asset Growth Rate (YoY) | -33.2% |
| Total Assets | €154.25 Million |
| Market Capitalization | $215.51 Million USD |
Valuation Analysis
Above Book Valuation: The market values AC IMMUNE SA SF-02's assets above their book value (1.40x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: AC IMMUNE SA SF-02's assets decreased by 33.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AC IMMUNE SA SF-02 (2021–2025)
The table below shows the annual total assets of AC IMMUNE SA SF-02 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €154.25 Million ≈ $180.34 Million |
-33.20% |
| 2024-12-31 | €230.91 Million ≈ $269.96 Million |
+26.31% |
| 2023-12-31 | €182.81 Million ≈ $213.73 Million |
-1.68% |
| 2022-12-31 | €185.94 Million ≈ $217.38 Million |
-28.88% |
| 2021-12-31 | €261.44 Million ≈ $305.65 Million |
-- |
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more